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Clostridium difficile strains within the hypervirulent clade 2 are responsible for nosocomial outbreaks worldwide. The increased
pathogenic potential of these strains has been attributed to several factors but is still poorly understood. During a C. difficile
outbreak, a strain from this clade was found to induce a variant cytopathic effect (CPE), different from the canonical arborizing
CPE. This strain (NAP1V) belongs to the NAP1 genotype but to a ribotype different from the epidemic NAP1/RT027 strain.
NAP1V and NAP1 share some properties, including the overproduction of toxins, the binary toxin, andmutations in tcdC.
NAP1V is not resistant to fluoroquinolones, however. A comparative analysis of TcdB proteins fromNAP1/RT027 and NAP1V
strains indicated that both target Rac, Cdc42, Rap, and R-Ras but only the former glucosylates RhoA. Thus, TcdB from hyper-
virulent clade 2 strains possesses an extended substrate profile, and RhoA is crucial for the type of CPE induced. Sequence com-
parison and structural modeling revealed that TcdBNAP1 and TcdBNAP1V share the receptor-binding and autoprocessing activi-
ties but vary in the glucosyltransferase domain, consistent with the different substrate profile. Whereas the two toxins displayed
identical cytotoxic potencies, TcdBNAP1 induced a stronger proinflammatory response than TcdBNAP1V as determined in ex vivo
experiments and animal models. Since immune activation at the level of intestinal mucosa is a hallmark of C. difficile-induced
infections, we propose that the panel of substrates targeted by TcdB is a determining factor in the pathogenesis of this pathogen
and in the differential virulence potential seen among C. difficile strains.
Clostridium difficile, a Gram-positive spore-forming anaerobe,is the leading cause of antibiotic-associated diarrhea in hospi-
talized patients (1). Antibiotic treatment modifies the balance of
commensal microbiota, allowing C. difficile to extensively colo-
nize the gut. The resulting C. difficile infection (CDI) leads to a
variety of clinical outcomes that range from mild diarrhea to po-
tentially fatal pseudomembranous colitis (2).
The main virulence factors associated with CDI are two large
exotoxins, TcdA and TcdB. The toxins are encoded by the tcdA
and tcdB genes, respectively, which are located in a 19.6-kb patho-
genicity locus (PaLoc) together with the tcdE (holin-like), tcdC
(putative negative regulator), and tcdR (sigma factor) genes (3, 4).
The toxins glucosylate small GTPases (5), and their combined
action results in colonic tissue inflammation and massive colonic
fluid secretion (2). In cell cultures treated with C. difficile toxins,
monoglucosylation of RhoA, Rac1, and Cdc42 disrupts the actin
cytoskeleton and causes an arborizing cytopathic effect (CPE) (5).
TcdB is a 270-kDa cytotoxin, and its mechanism of action in-
volves host cell receptor binding (6), uptake by endocytosis (7),
pH-dependent pore formation (8), translocation across the endo-
somalmembrane (9), host factor-dependent autoprocessing (10),
and release of the glucosyltransferase domain (GTD) into the host
cell (11). The C-terminal domain of the holotoxin contains a
number of short, homologous regions with combined repetitive
oligopeptides (CROPs) and is thought to be important for binding
host cell receptor(s) (11). The middle part of the toxin represents
the translocation region with autoprocessing activity mediated by
an autoprotease domain (9). The GTD located in the N-terminal
region is composed of a catalytic and a substrate recognition sub-
domain; this region is responsible for the cytopathic activity in the
host cell cytosol (12).
C. difficile strains producing a variant TcdB have been previ-
ously reported, mainly in TcdA-negative strains (13–15). In cul-
tured cells, these TcdB variants induce a CPE characterized by the
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collapse of the actin cytoskeleton with complete rounding of the
cell body and detachment from the surface in contrast to the clas-
sic arborizing effect (13). This variant CPE is due to a different
pattern of glucosylated GTPases since classic TcdB modifies
RhoA, Rac, and Cdc42 whereas variant TcdB targets Rac, Cdc42,
Rap, Ral, and R-Ras (5, 13, 14, 16). Furthermore, variations based
on the PaLoc sequence have classified these groups of strains in
separate toxinotypes (17).
The epidemic NAP1/RT027 C. difficile strains have rapidly
spread and have been responsible for epidemic outbreaks world-
wide (18, 19). Among the factors that have been proposed to con-
tribute to the increased virulence of these strains are resistance to
fluoroquinolones, higher sporulation capacity, and increased pro-
duction of toxins (20–22). It has been demonstrated that TcdB
from epidemic NAP1/RT027 strains possesses an increased cyto-
toxic capacity on different cell types due to a more efficient auto-
processing activity, which would result in a more rapid release of
the enzymatic domain into the cytosol (23). These results indicate
that altered TcdB activity could be an additional important factor
for the increased pathogenesis of NAP1 strains.
In this work, we describe a C. difficile NAP1 strain from the
hypervirulent clade 2 carrying a variant TcdB (TcdBNAP1V). In
contrast to TcdB from the classic NAP1/RT027 strain, TcdBNAP1V
does not glucosylate Rho and partially targets Cdc42.Whereas the
cytopathic potency of this TcdBNAP1V is similar to that of TcdB
purified from classic NAP1 strains, it induces a significantly lower
quantity of proinflammatorymediators in the ligated loopmodel,
suggesting that the panel of glucosylated small GTPases deter-
mines the biological outcome induced by C. difficile toxins.
MATERIALS AND METHODS
Isolation and characterization of C. difficile strains and fluoroquin-
olone resistance. The NAP1 strains were isolated from stool samples ac-
cording to the protocols previously described (24). Fragments of tcdA,
tcdB, cdtB, and tcdCwere amplified by PCR using primers and conditions
previously reported (25, 26). MICs of ciprofloxacin, moxifloxacin, and
levofloxacin were determined using agar dilution according to guidelines
of the Clinical and Laboratory Standards Institute (CLSI; M11-A7). Re-
sistance breakpoints were 4 g · ml1. Mutations in the fluoroquin-
olone resistance-determining region of gyrA and gyrB and in the tcdC
genes were identified using Artemis (27) and BLAST tools.
PFGE typing. The pulsed-field gel electrophoresis (PFGE) procedure
was derived from published protocols (28, 29). Bacteria from 6- to 8-h
cultures in brain heart infusion (BHI) were disrupted in lysis buffer. Aga-
rose plugs were prepared by mixing equal volumes of bacterial suspen-
sions and SeaKem Gold agarose (Lonza) in Tris-EDTA (TE) buffer con-
taining SDS. After overnight digestion with SmaI (Roche), DNA
fragments were separated on 1% agarose (Bio-Rad) gels. Images were ana-
lyzedwith the BioNumerics software, v5.1 (AppliedMaths), and the patterns
were compared to those deposited in the database of theNationalMicrobiol-
ogy Laboratory, Public Health Agency of Canada (Michael R. Mulvey).
PCR-restriction fragment length polymorphism (RFLP) analysis
and ribotyping. For toxinotyping, C. difficile VPI 10463 was used as a
control according to the published protocols (30). For ribotyping, primer
sequences and reaction conditionswere taken from thework of Bidet et al.
(31).
Whole-genome sequencing, MLST, and PaLoc/TcdB comparison.
Whole-genome sequences were obtained using multiplexed paired-end
libraries and the sequencing-by-synthesis HiSeq platform (Illumina).
Reads were assembled using Velvet (32), contigs of 300 bp were scaf-
folded with SSPACE (33), and gaps were filled using GapFiller (34). The
resulting scaffolds were ordered using Mauve (35) and the genomes of
reference strain R20291 (NAP1/RT027/ST01) or M68 (NAP9/RT017/
ST37). For automatic annotation, we used Prokka (36) and custom C.
difficile databases. For core genome multialignment, variant calling, and
core genome phylogeny, we used theHarvest suite (37) and FigTree (http:
//tree.bio.ed.ac.uk/software/figtree/). For multilocus sequence typing
(MLST), we used the MLST 1.7 tool maintained by the Center for
Genomic Epidemiology at the Danish Technical University (38). PaLoc
and TcdB sequences were extracted manually and aligned with MAFFT
(39) or MUSCLE (40). For these sequences, phylogenetic tree estimation
throughmaximum likelihood was done using Fasttree (41). TcdB recom-
bination was detected using DualBrothers (42).
Quantitation of secreted toxins. The NAP1V and NAP1 strains were
grown in TYT broth (3% Bacto tryptose, 2% yeast extract, and 0.1%
thioglycolate, pH 6.8) for 24 h, as described previously (29). Decimal
dilutions of these supernatants were added to HeLa cell monolayers. The
cells were monitored for appearance of CPE. Specific TcdB antiserum
(TechLab) was used to neutralize the effect of the toxin. Nontoxigenic C.
difficile ATCC 700057 was used as a negative control. Cytotoxicity was
expressed as the inverse of the dilution of the supernatants that caused
50% cell rounding in themonolayers (CPE50). The amount of toxins was
quantified by Western blotting, for which the proteins from bacteri-
um-free supernatants at 24 h were concentrated by methanol-chloro-
form precipitation (43). Proteins were separated in SDS-PAGE gels
and electrotransferred to polyvinylidene difluoride (PVDF) mem-
branes. The membranes were probed with monoclonal anti-TcdA
(TTC8) or anti-TcdB (2CV) antibody (tgcBIOMICS) (43). Chemilumi-
nescent signals emitted by a goat anti-mouse IgG-horseradish peroxidase
conjugate (Invitrogen) in the presence of the Lumi-Light Plus Western
blotting substrate (Roche) were recorded with a ChemiDoc XRS docu-
mentation system (Bio-Rad). Transcripts of tcdA and tcdBwere quantified
by real-time quantitative PCR (qRT-PCR) as described previously (44).
The amplification followed conditions previously reported (44). The rel-
ative expression of genes was calculated by the threshold cycle (CT)
method using rpoA transcript as the endogenous control (45).
Toxin purification. TcdB proteins were obtained from supernatants
of NAP1 strains grown in a dialysis system culture and purified as de-
scribed previously (46). The purity of the toxins was determined by SDS-
PAGE and mass spectrometry which indicated the presence of peptides
derived from TcdB only and not TcdA (data not shown).
Cytopathic effect produced by NAP1 toxins. Confluent 3T3 fibro-
blasts, Vero cells, and HeLa cells grown in 12-mm glass slides were intox-
icatedwith 0.2 nMTcdBNAP1 and TcdBNAP1V. The cells were immobilized
and fixed according to previously described protocols (47). The CPE was
evaluated by phase-contrast, fluorescence, and scanning electron micros-
copy as indicated in the figure legends.
In vitro glycosyltransferase activity. The TcdB ability to glycosylate
different monomeric GTPases was examined through a radioactivity as-
say, as previously described (48, 49), and Western blot assays. Briefly, for
the radioactive test, UDP-[14C]glucose (250 mCi/mmol; PerkinElmer),
GTD, each recombinant GTPase–glutathione S-transferase (GST), and
eachTcdBweremixed in a reaction buffer. After 1 h of incubation at 37°C,
the proteins were separated by SDS-PAGE. Glycosylation of GTPase was
analyzed by phosphorimaging. For graphical representation, band density
was measured with ImageQuant TL. For the Western blotting, the same
reactions and conditions were used and assays were performed using
UDP-glucose (Sigma). After protein separation by SDS-PAGE, the pro-
teins were transferred to PVDF membranes. The GTPase was detected
with monoclonal anti-RhoA antibody (Abcam; ab54835) by Western
blotting. The control RhoA-GST proteins were stained with Coomassie
blue.
RhoA, Rac1, and Cdc42 GTPase activation assays. The TcdB ability
to inactivate GTPases was determined on confluent 3T3 fibroblasts grown
in Dulbecco modified Eagle medium (DMEM) supplemented with 5%
fetal bovine serum (FBS) (Sigma). For the pulldown steps,GTP-RhoAwas
precipitatedwithGST-tagged Rho binding domain (RBD) andGTP-Rac1
andGTP-Cdc42 were precipitated with GST-p21 binding domain (PBD).
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Confluent 3T3 fibroblasts cultured in 6-well plates were intoxicated with
0.2 nM TcdB of NAP1V and NAP1 strains under the conditions indicated
in the figure legends. After the intoxication, the cells were treated as pre-
viously described (47). Briefly, cells werewashedwith phosphate-buffered
saline (PBS) and lysed with precipitation buffer. Lysates were centrifuged
and incubated with Rho binding domain (RBD) of the human Rhotekin
protein, which had been expressed as a GST fusion protein (RBD-GST),
or Rac/Cdc42 (p21) binding domain (PBD) of the human p21-activated
kinase 1 protein, which had been expressed as aGST fusion protein (PBD-
GST). Active proteins were pulled down by centrifugation, resolved by
SDS-PAGE, and transferred to PVDFmembranes. GTPases were detected
using anti-RhoA (Abcam; ab54835), anti-Rac1 (Abcam; ab33186), or an-
ti-Cdc42 (Abcam; ab41429) antibody by Western blotting. For detection
of RhoA glucosylation using the monoclonal antibody, HeLa cells, Vero
cells, and 3T3 fibroblasts were intoxicated with 0.2 nM TcdB from NAP1
or NAP1V strains for 6 and 24 h. After intoxication, cells were lysed in 2%
SDS and 20 g of each lysate was separated by 10% SDS-PAGE, electro-
transferred to PVDFmembranes, and probed with the anti-RhoAmono-
clonal antibody.
Structural analysis and TcdBGTDmodeling. The homologymodels
weremade usingModeler and Chimera bioinformatics tools, as described
previously (49), based on the tcdB sequences of NAP1, NAP1V, and VPI
10463 strains. Adjustments to the multiple-sequence alignment con-
structed by using ClustalW (50) were made based on the structure-based
alignment performed by superimposing the structures of TcdB proteins.
Kinetics of CPE induced by toxins. Confluent HeLa cells were intoxi-
catedwith10pMTcdBNAP1 andTcdBNAP1V.Thepercentageof roundcells in
each well was evaluated every hour for a period of 12 h and then at 24 h.
Determination of TNF- induction.ConfluentRAW264.7 cells were
intoxicated with 0.5 nM TcdBNAP1 and TcdBNAP1V for 6 h. The concen-
tration of tumor necrosis factor alpha (TNF-) in the supernatants was de-
termined by commercial enzyme-linked immunosorbent assay (ELISA) ac-
cording to the instructions of the manufacturer (R&D Systems).
Murine ileal loop model. Animal experimental procedures were ap-
proved (CICUA-38-14) by the University of Costa Rica Animal Care and
Use Committee. Male Swiss mice of 20 to 25 g were subjected to fasting
overnight and anesthetized with ketamine (60mg/kg of body weight) and
xylazine (5 mg/kg) (Eremer Pharma). Through a midline laparotomy, an
ileal loop was ligated, and 10 g of each toxin or the corresponding con-
trol solution was injected. Mice were sacrificed 4 h after inoculation, and
the length and weight of the intestinal loops were recorded (51). The
neutrophil accumulation in homogenized ileal tissue was evaluated
through determination of myeloperoxidase (MPO) activity with the o-
dianisidine dihydrochloride (Sigma) and H2O2 assay (52). The concen-
trations of the proinflammatory cytokines interleukin-1 (IL-1), IL-6,
and TNF- in ileal tissue homogenates were determined by commercial
ELISA according to the instructions of the manufacturer (R&D Systems).
Nucleotide sequence accession numbers. All reads were deposited at
the European Nucleotide Archive in study PRJEB5034 under the run ac-
cession numbers ERR467598 (LIBA-5784), ERR467603 (LIBA-6277),
ERR467599 (LIBA-5785), ERR467582 (LIBA-5757), and ERR467583
(LIBA-5758).
RESULTS
ANAP1 strain inducing a variant cytopathic effect. In a prelim-
inary study performed on a collection of clinical isolates from
tertiary care hospitals, the presence of the NAP1 genotype was
reported (24). Among 33 NAP1 isolates analyzed, we found a
strain whose supernatant induced a cytopathic effect (CPE) dif-
ferent from the classic arborizing CPE observed for the other
NAP1 strains (data not shown). PFGE analysis indicated that the
SmaImacrorestriction pattern of this particular variant strain was
279, while the pattern of the other NAP1 strains was 001 (Fig. 1A).
This strain, here designated NAP1V, was analyzed by whole-ge-
nome sequencing and comparative genome analyses. A phyloge-
netic reconstruction based on core single nucleotide polymor-
phisms (SNPs) revealed that NAP1V is more closely related to
historical and epidemic NAP1/RT027/ST01 strains than to TcdA-
negative NAP9/RT017/ST37 strains with genes encoding variant
TcdB (53) (Fig. 1B). This relationship to the clade 2 of hyperviru-
lent lineages postulated by Griffiths et al. (54) was confirmed
through ribotyping andMLST, as both the NAP1V (RT019/ST67)
and the NAP1 (RT027/ST01) strains belong to this clade (54). In
agreement with this finding, the NAP1V strain carries the tcdA,
tcdB, and cdtB genes and presents an 18-bp deletion and a single-
base-pair deletion at position 117 in tcdC, characteristic of NAP1/
RT027 strains. On the other hand, NAP1V was not resistant to
fluoroquinolones and did not present the amino acid transition
from Thr82 (ACT) to Ile (ATT) in GyrA as observed in classic
NAP1/RT027 strains (55).
The levels of secreted TcdA and TcdB and the expression of
tcdA and tcdB transcriptsweremeasured to determinewhether the
NAP1V strain produces increased amounts of toxin relative to the
classical epidemic NAP1/RT027 strain. Titration of toxin activity
in bacterium-free supernatants indicated that the NAP1 and
NAP1V strains induced similar CPE50 titers (Fig. 2A), and in
agreement, the levels of secreted toxins were similar for the two
strains (Fig. 2B). tcdA and tcdB mRNAs were quantified by real-
time quantitative PCR. The level of both transcripts was signifi-
FIG 1 PFGE and core genome-based analysis of the phylogenetic relatedness
of NAP1 strains analyzed. (A) Two different SmaI macrorestriction patterns
were detected, 001 and 279. The variant NAP1 strain was allocated to the latter
group, and thus, we named it NAP1V. NAP4 (TcdA
 TcdB) and NAP9
(TcdA TcdB) strains were included in the dendrogram for comparative
purposes. (B) A phylogenetic reconstruction based on core SNPs revealed that
the NAP1V strain was more closely related to NAP1 reference strains and
clinical isolates than to contemporary NAP2, NAP4, NAP6, and NAP9 clinical
isolates (four-digit identifiers after the PFGE pattern) and to CD_630 and VPI
10463 strains. The genomes of reference NAP1/RT027 (CD196, R20291, B1-
12, and BI17), NAP9/RT017 (M68), CD_630, and VPI 10463 strains were
included in the analysis to validate the results of the PFGE typing method.
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cantly higher in both theNAP1 andNAP1V strains than in control
strains at all times tested (Fig. 2C). Interestingly, theNAP1V strain
produces even more toxin transcripts than does the NAP1 coun-
terpart, a detail that should be considered in future experiments
dealingwith the regulation of these genes. Altogether, these results
demonstrate that the NAP1V strain is closely related to the epi-
demic NAP1/RT027 strains but displays distinctive genotypic and
phenotypic characteristics associated with TcdB that we further
explored.
TcdBNAP1V induces a variant CPE related to a distinct
GTPase glucosylation pattern. To analyze the cytopathic char-
acteristics of toxin B from NAP1V (TcdBNAP1V) and compare the
toxin with those from a classic NAP1 strain (TcdBNAP1), both
toxins were purified. After intoxication of HeLa cells, Vero cells,
and 3T3 fibroblasts with TcdBNAP1, the classical arborizing CPE
was observed (Fig. 3). In contrast, TcdBNAP1V induced cell round-
ing and detachment but no protrusions or arborizing effects (Fig.
3). Hence, TcdBNAP1V was responsible for the variant CPE pro-
duced by NAP1V supernatants.
Next, we determined the glucosylation pattern of TcdBNAP1
andTcdBNAP1V using a panel of smallGTPases and a radioactive in
vitro assay. TcdBNAP1 modified a panel of substrates characteristic
of classic TcdB proteins, with RhoA, Rac1, and Cdc42 being read-
ily glucosylated (Fig. 4A). Interestingly, we observedmodification
to a lesser extent of Rap1, Rap2, and R-Ras, which has not been
reported previously for classic TcdB proteins inducing arborizing
CPE. On the other hand, TcdBNAP1V glucosylated Rac1, but the
glucosylation of RhoA and Cdc42 was significantly diminished
(Fig. 4B). As with TcdBNAP1, TcdBNAP1V was able to glucosylate
Rap1, Rap2, and R-Ras at low levels.
To confirm the panel of substrates modified by the toxins, we
monitored the ex vivo glucosylation of RhoA, Rac1, and Cdc42
after intoxication of cultured cells by pulldown assays. When 3T3
cells were incubated with TcdBNAP1, Rho-GTP was undetectable
at 6 h (Fig. 4C). In contrast, Rho-GTP was detected in cells intox-
icated with TcdBNAP1V for up to 24 h, confirming the lack ofmod-
ification of this small GTPase in the in vitro assay (Fig. 4C). Both
TcdBproteins inactivatedRac1 after 6 and 24hof treatment, again
confirming the results of the in vitro glucosylation assay (Fig. 4C).
Additionally, the level of Cdc42-GTP exhibited a significant and
FIG 2 The NAP1V strain produces increased amounts of TcdA and TcdB. (A)
Twenty-four-hour bacterium-free supernatants were titrated by 10-fold dilu-
tions on HeLa cell monolayers. Twenty-four hours after inoculation with the
indicated supernatant, the dilution inducing a cytopathic effect (CPE) in 50%
of the cells was calculated by visual examination under the microscope. Each
bar represents themeans	 standard deviations ofCPE50 from three replicates.
*, P
 0.05 (one-way Kruskal-Wallis test followed by Mann-Whitney U test).
(B) Proteins from bacterium-free supernatants were precipitated and sepa-
rated by 7.5% SDS-PAGE. Proteins were electrotransferred to PVDF mem-
branes and probed with monoclonal antibodies to TcdA and TcdB. (C) Total
RNA was prepared from the indicated strains at 5, 8, and 24 h during the
growth curve. RNA was retrotranscribed, and cDNA was quantified by RT-
PCR using primers specific for tcdA and tcdB. Results displayed represent the
means	 standard deviations from three independent experiments. *,P
 0.05
compared to NAP4; **, P 
 0.05 compared to NAP1 (one-way analysis of
variance with Bonferroni’s correction).
FIG 3 The NAP1V strain induces a variant CPE. HeLa cells, Vero cells, and
3T3 fibroblasts were treated with TcdBNAP1 and TcdBNAP1V. Cells were treated
until a CPE was achieved in 100% of the cells. Images obtained by phase-
contrast microscopy show rounding as well as detachment of the cells caused
only by TcdBNAP1V. In order to see actin cytoskeleton modifications, fibro-
blasts were stained with fluorescein isothiocyanate-phalloidin. TcdBNAP1-
treated cells show a classical arborizing effect. TcdBNAP1V-treated cells that had
not been detached were fixed and show cell rounding without an arborizing
effect. Cells were visualized with a Nikon Eclipse 80i fluorescence microscope.
Effects on cells induced by the toxins were visualized by scanning electron
microscopy (SEM) using an S-3700N (Hitachi) electron microscope.
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consistent decrease at 6 h after intoxication with TcdBNAP1 and
Cdc42-GTP completely disappeared after 24 h of treatment (Fig.
4C). However, TcdBNAP1V was able to decrease the level of Cdc42-
GTP only after 24 h of intoxication, indicating that this small
GTPase is not a preferred substrate of this variant TcdB (Fig. 4C).
Interestingly, no signal was detected in the control for total Rho
(loading control) in cells treated with TcdBNAP1, indicating either
that the protein is degraded after glucosylation or that, alterna-
tively, the antibody to Rho that we used in this work does not
recognize the glucosylated isoform (Fig. 4C). To distinguish be-
tween these two possibilities, recombinant Rho was incubated
with either TcdBNAP1 or TcdBNAP1V in the presence of UDP-glu-
cose. Rhowas detected byCoomassie blue staining after treatment
with both toxins but was not detected by Western blotting after
treatment with TcdBNAP1 (Fig. 5A). This result indicates that the
monoclonal antibody used does not interact with glucosylated
Rho and confirms the fact that TcdBNAP1V does not modify this
small GTPase. Thus, this monoclonal antibody represents a valu-
able tool tomonitor Rhomodification by large clostridial cytotox-
ins. To further explore this concept, different cell lines (HeLa cells,
3T3 fibroblasts, and Vero cells) were intoxicated for 6 and 24 h
with either TcdBNAP1 or TcdBNAP1V. RhoA was detected only in
lysates prepared from cells intoxicated with TcdBNAP1V (Fig. 5B),
confirming that the ability to target this small GTPase is the main
difference at the level of substrates between the two toxins.
TcdBNAP1V sequence combines the enzymatic domain of
variant toxins with the receptor-binding domain of TcdB from
the hypervirulent clade 2. Since TcdBNAP1V clearly presents dif-
ferent phenotypic behavior than TcdBNAP1, we focused on differ-
ences at the sequence level. Phylogenetic analysis indicates that the
PaLoc of the NAP1V strain is more closely related to that of classic
NAP1/RT027 strains than to TcdA-negative strains carrying vari-
ant TcdB proteins (Fig. 6). Next, we determined the toxinotype of
the NAP1V strain. The tcdB polymorphisms of the B1 fragment
(containing the coding region for the TcdB glucosyltransferase
domain) (Fig. 7A) from NAP1V were identical to those of TcdA-
negative strain NAP9/RT017 and different from that of NAP1/
RT027 (Fig. 7B). The restriction patterns for tcdA were the same
for the two strains (Fig. 7C). Thus, the toxinotype of the NAP1V
strain (toxinotype XXIII) is not the classic one found in NAP1
strains (toxinotype III) and rather coincides with the toxinotype
present in TcdA-positive strains carrying variant TcdB proteins.
A detailed analysis and comparison of the sequences from the
different TcdB proteins indicates that the primary sequence of the
glucosyltransferase domain of TcdBNAP1V is more closely related
to the corresponding region of TcdB proteins inducing a variant
CPE than to that of TcdB proteins inducing a classic arborizing
CPE (Fig. 8A). Indeed, the identity in the first 546 amino acid
residues between TcdBNAP1V and TcdBNAP9 is 100%, whereas that
FIG 4 The NAP1V strain does not glucosylate RhoA. (A) TcdBNAP1 and
TcdBNAP1V were tested for their ability to glycosylate a panel of recombinant
GTPases using UDP-[14C]glucose as a cosubstrate. Labeled bands were de-
tected by phosphorimaging analysis. (B) The band intensities of the GTPase
glycosylation were quantified by densitometry. Each experiment was normal-
ized to Rac1 signal. Means 	 standard deviations from three independent
experiments are shown. (C) Effect of TcdBNAP1 and TcdBNAP1V on the activa-
tion state of small GTPases. 3T3 fibroblasts were intoxicated with TcdBNAP1
and TcdBNAP1V for the indicated times. After treatment, cells were lysed. One
part of the lysates was used as a control for total amount of GTPases, and the
other onewas incubatedwith PBD-GST or RBD-GST-Sepharose beads. Active
proteins were pulled down and analyzed by Western blotting. GTPases were
detected using anti-RhoA, anti-Rac, and anti-Cdc42, respectively. Cells treated
with TcdBNAP1 show inactivation of RhoA, whereas cells intoxicated with
TcdBNAP1V do not. Cytotoxic necrotizing factor 1 (CNF) from Escherichia coli
was used as a positive control for GTPase activation. Negative-control cells
were left untreated.
FIG 5 A monoclonal antibody to RhoA detects modification of this small
GTPase by TcdBNAP1 but not by TcdBNAP1V. (A) Recombinant purified RhoA
was incubatedwith TcdBNAP1 andTcdBNAP1V in the presence ofUDP-glucose.
The preparations were separated by SDS-PAGE and detected by Coomassie
blue staining. Parallel samples were transferred to PVDF membranes and de-
veloped by Western blotting (WB) using the monoclonal antibody to RhoA.
(B) HeLa cells, 3T3 fibroblasts, and Vero cells were treated for the indicated
times with TcdBNAP1 or TcdBNAP1V. Cell lysates of treated cells and nontreated
control cells were separated by SDS-PAGE, transferred to PVDFmembranes, and
revealedwith themonoclonal antibody toRhoAbyWesternblotting.As a loading
control, membranes were also revealed with a monoclonal antibody to Cdc42.
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between TcdBNAP1V and TcdBNAP1 is 80%. Furthermore, the
identity in the substrate specificity domain (amino acids 365 to
516) between TcdBNAP1V and TcdBNAP1 is only 62%. The glu-
cosyltransferase domain (GTD) sequences of TcdBNAP1V and
TcdBNAP1 were analyzed in the context of the VPI 10463 refer-
ence strain (identical to the 630 reference strain). Although the
core residues of the GTDs are conserved between TcdBNAP1V
and TcdBVPI10463, the surface residues are divergent (Fig. 8B).
These divergent residues are predicted to be involved in the sub-
strate affinity of the GTD. In contrast, the GTDs of TcdBNAP1 and
TcdBVPI10463 are very similar (Fig. 8B). The CROPs domain of
TcdBNAP1V is highly similar to the corresponding region of TcdB
proteins from classic NAP1 strains (Fig. 8A). The identity in this
region (amino acids 1645 to 2366) between TcdBNAP1V and
TcdBNAP1 is 99%.
These data indicate the possibility of a recombination event
that led to the sequence encoding TcdBNAP1V. To explore this, we
applied a Bayesian approach to infer changes in tree topologies
and evolutionary rates using TcdB sequences from strainsNAP1V,
R20291 (NAP1/RT027), M120 (NAP7/RT078), and NAP9/
RT017. Figure 8C shows the dominant tree topology within each
partition of the alignment, with NAP1V and NAP9/RT017 being
the closest neighbors with 100% probability in the first 635 resi-
dues of the alignment and NAP1V and R20291 (NAP1/RT027)
showing the same result from residue 1465 onward. These topol-
ogies imply a possible recombination event between TcdB pro-
teins from NAP1/RT027 and NAP9/RT017 strains.
TcdBNAP1V and TcdBNAP1 have similar cytopathic potencies
but exert different biological effects.To assess the cytopathic po-
tency of TcdBNAP1V and TcdBNAP1, both toxins were titrated on
HeLa cells. The two toxins elicited similar kinetic profiles of cell
intoxication, indicating that their cytopathic potencies are similar
(Fig. 9A). TcdBNAP1V and TcdBNAP1 were also tested for their abil-
ity to induce TNF- production by RAW murine macrophages.
Despite the similar cytopathic potencies, the release of this cyto-
kine was statistically higher in cells treated with TcdBNAP1 (Fig.
9B). The pathogenic potential of both toxins was assayed in the
murine ligated ileal loop model. We measured the concentration
of myeloperoxidase (MPO) activity as an indicator of tissue neu-
trophil infiltration and the levels of IL-1 and IL-6 to indicate
immune activation at the ileal tissue level. TcdBNAP1 caused a sta-
tistically significant increase in MPO activity, whereas TcdBNAP1V
elicited a reaction undistinguishable from that of the control (Fig.
9C). The levels of IL-1 and IL-6 were significantly increased by
TcdBNAP1, and again, TcdBNAP1V was unable to induce any reac-
tion (Fig. 9C).
DISCUSSION
The increase in rate and severity of CDI has been linked to the
emergence and spread of the epidemic NAP1 strain (19, 56). This
genotype has acquired several genetic determinants that contrib-
ute to its increased virulence; among these, the overproduction of
toxins (linked to mutations in the tcdC gene), the presence of a
binary toxin, and resistance to fluoroquinolones have been con-
sidered to play an important role (21, 22, 56). It has been shown
that TcdB is essential forC. difficile virulence and that its glucosyl-
transferase activity is required for activity in an ileal loop model
(57, 58). In this context, previous studies have concluded that
variations in the sequence of this toxin lead to an augmented cy-
topathic potency and play a crucial role in the increased virulence
of NAP1 strains. This increased cytotoxicity is due to a more effi-
cient delivery of the enzymatic domain to the cytosol (23, 59).
However, the role of the substrate pattern of TcdB within the
hypervirulent clade 2 has not been analyzed. In the present study,
we describe aNAP1 isolate from an outbreak setting that produces
FIG 7 Toxinotyping of NAP1 strains. The polymorphisms obtained from the
B1 and A3 regions of the tcdA and tcdB genes were analyzed by digestion with
AccI (A) and HindIII (H) restriction enzymes. (A) Representation of the am-
plified regions. (B) The restriction polymorphisms of the tcdB fragments from
the NAP1V (toxinotype XXII) and the tcdA-negative tcdB
NAP9 (toxinotype
VIII) strains are indistinguishable and different from the corresponding pat-
tern from the NAP1 strain. (C) The NAP1V and NAP1 (toxinotype III) strains
have the same restriction pattern of the tcdA fragment.
FIG 6 Phylogenetic relationship of the pathogenicity locus (PaLoc) of NAP1V
and NAP1 strains to that of reference strains (VPI 10463, CD_630, NAP7/
RT078_M120, NAP9/RT017_M68, and NAP1/RT027_R20291) and clinical
isolates (NAP4, NAP6, and NAP9). The PaLoc sequence of NAP1V clustered
together with those of clinical (NAP1-001_5768) and reference NAP1/027
(R20291) strains rather than with sequences from TcdA TcdB variant
strains (NAP9/017).
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a variant TcdB. Our goals were to understand the differences in
the CPEs induced by this toxin and the potential role of the panel
of modified substrates in the biological effects induced by TcdB
proteins secreted by strains from the hypervirulent clade 2 and to
elucidate the emergence of this NAP1 variant strain.
Due to the PFGE classification and the particular CPE induced
by bacterium-free supernatants derived from the NAP1V strain,
we reasoned that this isolate would have phenotypic characteris-
tics associated with important differences at the level of TcdB. The
NAP1V strain is, in fact, a toxin-overproducing isolate, harboring
deletions in tcdC and carrying the binary toxin gene. Nonetheless,
it is not resistant to fluoroquinolones, since it does not harbor the
typical mutation in gyrA found in NAP1 strains (60). Despite the
strain belonging to theNAP1/RT027 genotype, theNAP1V/RT019
macrorestriction pattern differs from that of the classical NAP1/
RT027 strains and its toxinotype differs due to variations within
the tcdB-encoded N-terminal region. Indeed, the digestion pat-
tern of the amplified B1 fragment coding for the catalytic region of
TcdBNAP1V was indistinguishable from the corresponding one
presented in TcdA-negative strains. Interestingly, the NAP1V
strain belongs to the toxinotype XXII, which has been described in
isolates harboring variant TcdB proteins (17, 61).
The CPE induced by TcdBNAP1V, characterized by rounding
and detachment of intoxicated cells, resembles the effect induced
by Clostridium sordellii lethal toxin (TcsL) and C. difficile variant
TcdB proteins (13, 62).This effect, referred to as variant CPE, was
FIG 8 TcdBNAP1V shares with TcdBNAP1 the receptor-binding domain but not the enzymatic domain. (A) Sequence alignment of (i) variant toxins B from
NAP9_M68, CD_1470, and CD_8864 reference strains inducing a variant (V) CPE; (ii) TcdBNAP1 from a clinical isolate and a reference epidemic NAP1/RT027
strain (R20291) inducing a classic (C) CPE; and (iii) TcdBNAP1V. Black lines represent disagreements in the sequence of TcdBVPI10463, which was selected as a
reference for the alignment. The blue box highlights a distinct glucosyltransferase region shared between NAP1V and other variant strains. The green box shows
sequence stretches in the repetitive CROPs domains shared between TcdBNAP1, TcdBR20291, and TcdBNAP1V. (B) Comparison of the TcdBNAP1 and TcdBNAP1V
sequences in the context of the TcdB GTD structure (PDB 2BVM, VPI 10463 sequence). Sequence conservation on the putative GTPase-binding face compared
to the GTD from C. difficileVPI 10463 with NAP1 and NAP1V TcdB GTD structures is shown (red, conserved; blue, not conserved). UDP-glucose is depicted in
white in the GTD active site. (C) Resulting recombination detection graphs using TcdB sequences from strains NAP9 (M68, RT017 reference strain), R20291
(epidemic NAP1/RT027 reference strain), NAP7 (epidemic M120, RT078 reference strain), and NAP1V. Signs of possible recombination events are represented
as changes in the topology graphs (first row) that appear at the most probable topology between the segments. The cross of the topological lines (green and red
lines) indicates recombination breakpoints. Resulting trees are compatible with a scenario in which TcdBNAP1V emerged through recombination of tcdB
sequences from NAP9 and NAP1 strains.
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first reported in C. difficile strains that do not produce TcdA.
While it has now been described in awider range of strains (13, 17,
47), it had not been previously described within the NAP1/RT027
genotype; in all these cases, the variant CPE has been attributed to
TcdB (16). The induction of a variant CPE by variant TcdB pro-
teins correlates with substrate profiles that differ from the panel
targeted by TcdB from reference strain VPI 10463. Whereas the
latter modifies Rho, Rac, and Cdc42, variant TcdB proteins also
modify R-Ras, Rap, andRal (5, 47). Amore detailed analysis of the
consequences of small GTPase modification indicated that R-Ras
glucosylation and transient RhoA activation determine the ap-
pearance of a variant CPE since R-Ras glucosylation leads to in-
tegrin inactivation, and as a consequence, focal adhesions disas-
semble, causing detachment (47). In contrast to TcdB from strain
VPI 10463, TcdBNAP1, which induces a classic arborizing CPE,
seems to have an extended substrate pattern since it was able to
modify Rap andR-Ras. These additional targeted substratesmight
have a role in the increased biological effects induced by TcdBNAP1
(57, 59). Interestingly, themain difference at the level of substrates
between TcdBNAP1V and TcdBNAP1 is the modification of RhoA.
Thus, the ability to target this small GTPase also seems to play an
important role in defining the type of CPE that will be induced,
since RhoA-modifying toxins induce an arborizing CPE and non-
RhoA-modifying toxins induce a variant CPE (63). In addition,
previous studies have shown that Cdc42 is not glycosylated by
variant TcdB proteins, but in the case of TcdBNAP1V, there is par-
tial modification of this small GTPase. However, a complete glu-
cosylation of Cdc42, as determined by pulldown assays, was de-
tected only after 24 h of intoxication, indicating that glucosylation
of this protein is not involved in induction of the variant CPE,
which appears in the first few hours after addition of the toxin.
There is a clear correlation between the small GTPases modi-
fied and the type of CPE induced by TcdBNAP1V and variant TcdB
proteins from TcdA-negative strains. This concordance is in
agreement with the primary sequence of the toxins since the GTD
of TcdBNAP1V has a high identity to the corresponding domain
found in variant TcdB proteins. On the other hand, the autopro-
cessing domain and the carboxyl-terminal region of TcdBNAP1V
are almost identical to the corresponding regions from TcdBNAP1.
These results, along with sequence comparison, reveal that
TcdBNAP1V is a toxin of the classical NAP1/RT027 genotype but
with modifications within the enzymatic domain.
Recently, a strain belonging to clade 2, RT244/ST41, was re-
ported to display an increased virulence (62). As a NAP1 strain,
RT244/ST41 harbors a binary toxin; however, it does not produce
increased amounts of toxins and is fluoroquinolone susceptible.
These data indicate that the NAP1V/RT019 strain shares more
features with the classic NAP1/RT027 than RT244/ST41 and
would then be more closely related to the epidemic strain. Inter-
estingly, the strain RT244/ST41 genome also seems to encode a
variant TcdB. A comparative and detailed assessment of the viru-
lence potential of these three strains would allow one to determine
the relative contribution of factors such as the presence of binary
toxin, overproduction of toxins, fluoroquinolone resistance, and
type of toxin produced to the increased virulence displayed by
members of this clade.
Nosocomial outbreaks caused by TcdA-negative strains have
increased in the last decade (53, 64, 65). Interestingly, all these
strains have been reported to harbor variant TcdB proteins. This
might be an indication that the biological effects induced by classic
TcdB proteins differ from those induced by variant TcdB proteins
and that TcdA-negative strains compensate for the lack of this
toxin by using a TcdB with a different panel of substrates. When
we compared the responses to TcdB on the ligated loopmodel, we
could indeed find a significant biological difference between the
two toxins. Whereas TcdBNAP1 induced an immune activation,
TcdBNAP1V induced a much milder and almost undetectable re-
sponse. Secretion of TNF- by macrophages has been associated
with the glucosyltransferase activity of C. difficile toxins (66), and
since TcdBNAP1V and TcdBNAP1 have a high degree of identity in
the regions determining receptor binding and entrance to the cell
and the two toxins have similar cytopathic potencies, we assume
that the biological differences detected in our assays are due to a
differential panel of substrates glucosylated. Since themain differ-
ence in substrates is at the level of RhoAmodification, we hypoth-
esize that glucosylation of this small GTPase enhances the proin-
flammatory response induced by C. difficile toxins. The use of a
panel of purified toxins with differing substrate panels like the
ones indicated in this article in a wide range of experimental mod-
els would allow the dissection of the relevance of the modification
of different small GTPases in the outcome of CDI.
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